Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sana Biotechnology Inc (SANA)

Sana Biotechnology Inc (SANA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,331,830
  • Shares Outstanding, K 266,366
  • Annual Sales, $ 0 K
  • Annual Income, $ -266,760 K
  • EBIT $ -240 M
  • EBITDA $ -223 M
  • 60-Month Beta 1.95
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.01

Options Overview Details

View History
  • Implied Volatility 98.39% (-3.95%)
  • Historical Volatility 110.59%
  • IV Percentile 4%
  • IV Rank 3.54%
  • IV High 833.42% on 01/06/25
  • IV Low 71.43% on 04/16/25
  • Expected Move (DTE 2) 0.25 (4.93%)
  • Put/Call Vol Ratio 0.23
  • Today's Volume 679
  • Volume Avg (30-Day) 1,752
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 52,321
  • Open Int (30-Day) 48,144
  • Expected Range 4.75 to 5.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.12
  • Number of Estimates 5
  • High Estimate -0.09
  • Low Estimate -0.15
  • Prior Year -0.23
  • Growth Rate Est. (year over year) +47.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.16 +58.23%
on 11/21/25
5.49 -8.93%
on 12/04/25
+1.01 (+25.31%)
since 11/14/25
3-Month
2.93 +70.65%
on 09/22/25
6.55 -23.66%
on 10/15/25
+1.90 (+61.29%)
since 09/16/25
52-Week
1.26 +296.83%
on 04/04/25
7.30 -31.51%
on 01/08/25
+3.04 (+155.10%)
since 12/16/24

Most Recent Stories

More News
Platform Oncology Technologies Drive Multi-Indication Treatment Expansion

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Artificial intelligence and platform-based approaches reshaped cancer treatment development in November...

ONCY : 1.0400 (+12.68%)
SANA : 5.00 (-1.57%)
ABSI : 3.55 (+4.72%)
RXRX : 4.20 (unch)
TEM : 68.11 (-0.82%)
Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform

Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in Preclinical Murine Models Using Fusogen Technology  Broadens Application...

SANA : 5.00 (-1.57%)
Sana Biotechnology to Present at December 2025 Investor Conferences

SEATTLE, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast...

SANA : 5.00 (-1.57%)
Sana: Q3 Earnings Snapshot

Sana: Q3 Earnings Snapshot

SANA : 5.00 (-1.57%)
Sana Biotechnology Reports Third Quarter 2025 Financial Results and Business Updates

Announced increased focus on type 1 diabetes and in vivo CAR T programs Regulatory interactions increase confidence in moving forward with GMP master cell bank for SC451, nonclinical testing plan,...

SANA : 5.00 (-1.57%)
Sana Biotechnology to Present at the TD Cowen Immunology & Inflammation Summit

SEATTLE, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast...

SANA : 5.00 (-1.57%)
3 Stocks to Buy Under $10 That Could Triple From Here

Not all great investment opportunities are expensive.

IOVA : 2.25 (+4.17%)
BCYC : 7.31 (-0.27%)
SANA : 5.00 (-1.57%)
Sana Biotechnology to Present at September 2025 Investor Conferences

SEATTLE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast...

SANA : 5.00 (-1.57%)
Biotechs Big Bang: IPOs, Uplists and the Short Squeeze Effect

When a microcap %Biotech transitions from obscurity to the Nasdaq Capital Market, fireworks are common. The move often signals a pivotal moment in the company's growth trajectory, opening the door to broader...

SANA : 5.00 (-1.57%)
RHHVF : 399.1600 (-0.75%)
$SANA : 3,452.65 (+8.59%)
PPCB : 0.7310 (-2.51%)
MRNA : 29.89 (-0.10%)
Sana Biotechnology Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares

SEATTLE, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that...

SANA : 5.00 (-1.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Sana Biotechnology Inc. is focused on creating and delivering engineered cells as medicines for patients. The company involved in repairing and controlling genes, replacing missing or damaged cells as well as making its therapies. Sana Biotechnology Inc. is based in SEATTLE.

See More

Key Turning Points

3rd Resistance Point 5.67
2nd Resistance Point 5.48
1st Resistance Point 5.24
Last Price 5.00
1st Support Level 4.81
2nd Support Level 4.62
3rd Support Level 4.38

See More

52-Week High 7.30
Last Price 5.00
Fibonacci 61.8% 4.99
Fibonacci 50% 4.28
Fibonacci 38.2% 3.57
52-Week Low 1.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar